BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) today announced the presentation of a scientific poster addressing the potential ability of its clinical compound, cobiprostone, to reduce cellular death and promote the regrowth of cells damaged by indomethacin, a commonly prescribed non-steroidal anti-inflammatory drug, or NSAID. The poster was presented yesterday at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia.
